NCT04401748: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Sponsor: AbbVie. Phase: PHASE3. Conditions: Myelodysplastic Syndrome (MDS)